Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study
| Autor: | Roula El Hachem, Joseph Kattan, Georges Chahine, Aline Hajj, Lydia Rabbaa Khabbaz, Fadi El Karak, Souheil Hallit, F. Nasr, Rita Khoury, Bashar ElJEBBAWI |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Cross-sectional study Breast Neoplasms Anxiety Hospital Anxiety and Depression Scale Risk Assessment Fosaprepitant 03 medical and health sciences 0302 clinical medicine Breast cancer Quality of life Internal medicine Genetics Insomnia medicine Humans Genetic Predisposition to Disease Public Health Surveillance Depression (differential diagnoses) RC254-282 Aged HADS business.industry Depression Research Neoplasms. Tumors. Oncology. Including cancer and carcinogens PER2 Middle Aged medicine.disease COMT Cross-Sectional Studies Oncology Pharmacogenetics 030220 oncology & carcinogenesis Female Disease Susceptibility medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021) BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background Despite the progress in assessment and treatment of breast cancer, being diagnosed with it or receiving chemotherapy treatment is still conceived as a traumatic experience. Women develop negative thoughts about life and death with detrimental effects on their daily physical functioning/activities, emotional state and overall quality of life. The aim of our study was to evaluate the level of anxiety and depression among breast cancer patients receiving chemotherapy and explore the correlation between these psychological disorders, clinical, sociodemographic and genetic factors. Methods A cross-sectional study was conducted among breast cancer patients undergoing intravenous chemotherapy at the oncology outpatient unit of Hôtel-Dieu de France hospital (November 2017–June 2019; Ethical approval number: CEHDF1016). All patients gave their written informed consent and completed several validated scales, including the Hospital Anxiety and Depression scale (HADS) for the assessment of anxiety and depression. Sleep quality, insomnia, cognitive function, fatigue and pain were also evaluated. Genotyping for certain gene polymorphisms (CLOCK, PER2, CRY2, OPRM1, ABCB1, COMT, DRD2) was performed using the Lightcycler® (Roche). Results A total of 112 women was included. The prevalence of depression was 43.4%, and 56.2% of the patients reported anxiety (based on the HADS classification). Multivariable analysis showed that higher cognitive scores and taking fosaprepitant were significantly associated with lower depression and anxiety scores. Moreover, being married compared to single was also associated with lower depression scores, whereas higher PSQI scores (worse sleep quality) and having the PER2 AA variant genotype compared to GG were significantly associated with higher depression scores. Finally, reporting a more severe insomnia and having the COMT Met/Met genotype were significantly associated with a higher anxiety score. Conclusions Our study demonstrated a strong relationship between depression scores and cognitive impairment, sleep quality, marital status, fosaprepitant intake, and PER2 polymorphism, while anxiety scores were correlated to cognitive impairment, insomnia severity, fosaprepitant intake, and COMT polymorphism. The association with PER polymorphism was not previously reported. Identification of genetic and clinical risk factors for anxiety and depression would help clinicians implement an individualized management therapy aiming at preventing and alleviating the burden of these symptoms in breast cancer patients, hence improving their overall quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|